Agree they're not looking to treat 100% of potential addressable OA market. Some doctors and patients won't ever consider injectables. The sweet spot for OA sufferers seems to be NRS 4-6 or patients not achieving any benefit for current standard of care and not ready for knee replacement. Irrespective we're likely to get on the PBS and the actual amount taxpayers subsidies initially is not going into the $B immediately rather will build over time. FDA is the main game.
Ann: Paradigm AGM Presentation, page-128
-
- There are more pages in this discussion • 14 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
24.5¢ |
Change
-0.015(5.77%) |
Mkt cap ! $85.70M | |||
| Open | High | Low | Value | Volume |
| 26.0¢ | 26.0¢ | 24.5¢ | $265.4K | 1.050M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 130186 | 24.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 25.0¢ | 11571 | 1 |
View Market Depth
| Last trade - 16.10pm 31/07/2024 (20 minute delay) ? |
| PAR (ASX) Chart |